Data expectations for structural, functional and clinical packages in 351 k Data expectations for structural, functional and clinical packages in 351 k The development of biosimilars is an intricate process governed by specific regulatory pathways that ensure the safety, efficacy, and quality of these biologics. The US biosimilar regulatory pathway, particularly under section 351(k) of the Public Health Service Act, outlines the framework for the approval of biosimilar products. This article serves as a comprehensive regulatory explainer manual, focusing on the data expectations for structural, functional, and clinical packages within the context of 351(k) applications. Context The U.S. biosimilar regulatory…

Totality of evidence approach explained for US biosimilar 351 k approvals Totality of Evidence Approach Explained for US Biosimilar 351(k) Approvals The regulatory landscape surrounding biosimilars continues to evolve significantly, particularly in the context of the United States. With the introduction of the 351(k) pathway under the Biologics Price Competition and Innovation Act (BPCIA), the US FDA provides a defined route for the approval of biosimilars. This article serves as a comprehensive regulatory explainer manual, detailing the totality of evidence approach required for biosimilar applications under 351(k), emphasizing compliance with the necessary regulatory frameworks, guidelines, and practical considerations for regulatory…

Leveraging FDA biosimilar guidances to shape your 351 k submission Leveraging FDA biosimilar guidances to shape your 351 k submission Regulatory Affairs Context The regulatory landscape for the development and approval of biosimilars in the United States is governed primarily by the Biologics Control Act and the Biologics Price Competition and Innovation Act, which established the 351(k) pathway for the approval of biosimilars. This pathway allows for a more streamlined process compared to a traditional Biologics License Application (BLA), balancing the need for robust data with the objective of promoting market competition and patient access to biologics. Understanding the US…

Governance and Cross Functional Ownership of the 351(k) BLA Program Governance and Cross Functional Ownership of the 351(k) BLA Program The development of biosimilars has emerged as a significant pathway to promote competition, reduce drug costs, and enhance patient access to biologics. The U.S. biosimilar regulatory pathway, particularly the 351(k) application under the Biologics Control Act, requires tight coordination between various functions in regulatory affairs, CMC, clinical development, and market access. This regulatory explainer manual aims to provide a comprehensive understanding of the 351(k) Biologics License Application (BLA) program, elucidating the governance structure, cross-functional responsibilities, and documentation requirements essential for…

Case examples of successful 351 k biosimilar approvals and lessons learned Case examples of successful 351 k biosimilar approvals and lessons learned Biosimilars have gained significant traction in recent years as effective alternatives to reference biologics. The United States regulatory framework established by the Biologics Price Competition and Innovation Act (BPCIA), particularly under the Section 351(k) pathway, outlines the requirements for biosimilar applications. This article serves as a comprehensive guide to navigating the US biosimilar regulatory pathway, particularly the 351(k) Biologics License Application (BLA), by examining successful case examples and highlighting critical lessons learned. Context The increasing cost of biologic…